GO:0001790 polymeric immunoglobulin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001790 polymeric immunoglobulin binding is a molecular function defined as binding to a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes.
• The polymeric immunoglobulin receptor (pIgR) is the archetypal protein that executes this function, mediating transcytosis of dimeric IgA and pentameric IgM across epithelial cells.
• This binding event is central to mucosal immunity, as it enables secretion of polymeric immunoglobulins into mucosal secretions and contributes to immune exclusion.
• Dysregulated polymeric immunoglobulin binding and clearance are implicated in IgA nephropathy, where charge-dependent interactions of polymeric IgA1 with mesangial cells drive glomerular injury.
• Engineered polymeric immunoglobulin-binding proteins and nanobody-displaying scaffolds are emerging as tools for targeted therapeutics and diagnostics.
• CRISPR-based knockout, knock-in, and overexpression models of pIgR and associated genes enable causal dissection of polymeric immunoglobulin binding in mucosal and renal disease.
Description
Polymeric immunoglobulin binding (GO:0001790) is a molecular function that describes the selective recognition of J-chain-containing polymeric immunoglobulins of the IgA or IgM isotypes. This function is essential for the transport and immune surveillance of mucosal surfaces, where polymeric IgA and IgM are captured and shuttled across epithelial barriers. The best-characterized mediator of this activity is the polymeric immunoglobulin receptor (pIgR), which binds dimeric IgA and pentameric IgM and mediates their transcytosis. Researchers study GO:0001790 to understand how mucosal immunity is established and maintained, and how defects in this process contribute to diseases such as IgA nephropathy. The function also has biotechnological relevance, as engineered binding proteins and nanobody-displaying platforms exploit polymeric immunoglobulin recognition for targeted delivery and diagnostics. Because the interaction is highly specific for J-chain-containing polymeric immunoglobulins, it serves as a paradigm for studying multivalent ligand-receptor recognition and transport.
polymeric immunoglobulin binding At A Glance
| GO ID | GO:0001790 |
|---|---|
| GO term | polymeric immunoglobulin binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes. |
| Major function | Recognition and capture of polymeric IgA and IgM for transport, immune exclusion, and clearance. |
| Representative protein | Polymeric immunoglobulin receptor (pIgR) |
| Related ligands | Dimeric IgA, pentameric IgM, J chain |
| Disease relevance | IgA nephropathy, mucosal infections, and inflammatory conditions |
What Is GO:0001790?
GO:0001790 polymeric immunoglobulin binding is defined as the binding to a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes. In other words, it is the molecular function of selectively attaching to multimeric IgA or IgM complexes that contain a joining (J) chain, rather than to monomeric immunoglobulins or other isotypes.
Why Is polymeric immunoglobulin binding Important in Cell Biology?
Polymeric immunoglobulin binding is a cornerstone of mucosal immunity because it enables the selective capture and transcytosis of dimeric IgA and pentameric IgM, which are the principal antibodies protecting mucosal surfaces. Without this function, secretory IgA and IgM cannot be efficiently transported into secretions, compromising immune exclusion of pathogens. The interaction is also clinically significant because abnormal handling of polymeric IgA is linked to IgA nephropathy, a common cause of glomerulonephritis. Furthermore, the specificity of this binding event makes it an attractive target for engineering recombinant receptors, nanobodies, and targeted therapeutics.
• Mediates transcytosis of dimeric IgA and pentameric IgM across epithelial cells.
• Essential for formation of secretory IgA and secretory IgM in mucosal secretions.
• Contributes to immune exclusion of pathogens at mucosal surfaces.
• Dysregulated polymeric IgA binding to mesangial cells is implicated in IgA nephropathy.
• Provides a model for multivalent ligand-receptor recognition and transport.
• Enables engineering of polymeric immunoglobulin-binding proteins for diagnostics and therapeutics.
• Relevant to mucosal vaccine design and passive immunization strategies.
• Supports studies of J-chain-dependent immunoglobulin assembly and function.
• Potential target for modulating mucosal inflammation and autoimmunity.
• Facilitates development of nanobody-displaying platforms for targeted delivery.
Molecular Mechanism of polymeric immunoglobulin binding
Recognition of J-chain-containing polymeric IgA and IgM
In simple terms: The binding protein must first recognize and attach to the correct antibody form.
The polymeric immunoglobulin receptor (pIgR) specifically binds to dimeric IgA and pentameric IgM that contain a J chain, distinguishing them from monomeric immunoglobulins. This selectivity ensures that only polymeric forms are transported across epithelia. The interaction is non-covalent and depends on the quaternary structure of the immunoglobulin complex.
Transcytosis across epithelial cells
In simple terms: After binding, the receptor carries the antibody across the cell to the other side.
Following binding, the pIgR-IgA/IgM complex is internalized and transported across the epithelial cell in a process called transcytosis. This movement delivers the polymeric immunoglobulin to the apical surface, where it is released into mucosal secretions. The transcytotic pathway is essential for generating secretory IgA and IgM.
Release and secretory component formation
In simple terms: The receptor is cut and part of it stays attached to the antibody, forming the secretory component.
At the apical membrane, the extracellular domain of pIgR is cleaved, releasing the immunoglobulin bound to a fragment of the receptor known as the secretory component. This secretory component remains associated with the immunoglobulin, forming secretory IgA or secretory IgM, which are stable in mucosal environments.
Charge-dependent interactions in disease
In simple terms: In some diseases, the binding is influenced by electrical charge and can cause harm.
In IgA nephropathy, charge-dependent binding of polymeric IgA1 to human mesangial cells contributes to glomerular injury. This highlights that polymeric immunoglobulin binding can occur in non-mucosal contexts and drive pathology when dysregulated.
Engineering and therapeutic exploitation
In simple terms: Scientists can use this binding function to build new tools and treatments.
The specificity of polymeric immunoglobulin binding has inspired engineered binding proteins, nanobody-displaying flagellar nanotubes, and ligand-targeted therapeutics. These platforms exploit the recognition of polymeric immunoglobulins for targeted delivery and diagnostic applications.
Key Genes Involved in GO:0001790 polymeric immunoglobulin binding
The following genes and proteins are directly or indirectly involved in polymeric immunoglobulin binding, its regulation, and its physiological consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PIGR | Encodes the polymeric immunoglobulin receptor that binds dimeric IgA and pentameric IgM | Central mediator of GO:0001790; knockout and knock-in models reveal transcytosis defects |
| JCHAIN | Encodes the joining chain that links immunoglobulin monomers into polymeric forms | Required for formation of J-chain-containing IgA and IgM; essential for pIgR binding |
| IGHA1 | Encodes IgA1 heavy chain | Forms dimeric IgA1; charge-dependent binding to mesangial cells in IgA nephropathy |
| IGHA2 | Encodes IgA2 heavy chain | Forms dimeric IgA2; contributes to mucosal immunity |
| IGHM | Encodes IgM heavy chain | Forms pentameric IgM; ligand for pIgR-mediated transcytosis |
| IGLL1 | Encodes lambda-like light chain involved in B cell development | May influence immunoglobulin assembly and polymeric forms |
| CD79A | B-cell receptor signaling component | Indirectly affects immunoglobulin production and polymeric IgA/IgM levels |
| CD79B | B-cell receptor signaling component | Indirectly affects immunoglobulin production and polymeric IgA/IgM levels |
| AICDA | Activation-induced cytidine deaminase | Required for class switching to IgA and IgM |
| PRDM1 | Transcription factor controlling plasma cell differentiation | Regulates immunoglobulin secretion including polymeric forms |
| XBP1 | Transcription factor in the unfolded protein response | Supports plasma cell expansion and immunoglobulin secretion |
| C1GALT1 | Glycosyltransferase for O-glycosylation of IgA1 | Altered glycosylation affects polymeric IgA1 clearance and mesangial binding |
| C1GALT1C1 | Chaperone for C1GALT1 | Defects lead to abnormal IgA1 glycosylation linked to IgA nephropathy |
| ST6GALNAC2 | Sialyltransferase modifying IgA1 | Modulates IgA1 charge and binding properties |
| FCAR | IgA Fc receptor (CD89) | Binds IgA and may cooperate with pIgR in IgA clearance |
| ITGAM | Integrin alpha-M (CD11b) | May participate in IgA-mediated cell interactions |
| TNFRSF13B | Transmembrane activator and CAML interactor | Regulates IgA production and mucosal immunity |
| TNFSF13 | APRIL cytokine | Promotes IgA class switching and plasma cell survival |
How Is polymeric immunoglobulin binding Regulated?
Polymeric immunoglobulin binding is regulated at multiple levels. Expression of the polymeric immunoglobulin receptor (PIGR) is modulated by cytokines and microbial signals, influencing the capacity for IgA and IgM transcytosis. The availability of J-chain-containing polymeric immunoglobulins depends on B-cell differentiation and class switching, which are controlled by factors such as AICDA, PRDM1, and XBP1. Post-translational modifications, including O-glycosylation of IgA1, affect the charge and binding properties of polymeric IgA, as seen in IgA nephropathy. Additionally, the unfolded protein response and plasma cell transcription factors regulate immunoglobulin secretion, indirectly controlling the amount of ligand available for binding.
polymeric immunoglobulin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIGR | Mucosal immune deficiency; impaired IgA/IgM transcytosis | PIGR knockout epithelial cell lines and organoids |
| C1GALT1 | IgA nephropathy; abnormal IgA1 glycosylation | Knockout or point-mutation in IgA-producing cell lines |
| C1GALT1C1 | IgA nephropathy; defective IgA1 glycosylation | Knock-in of patient variants in B cells |
| IGHA1 | IgA nephropathy; polymeric IgA1 deposition | Overexpression of IgA1 in mesangial co-culture models |
| JCHAIN | Defective polymeric immunoglobulin assembly | JCHAIN knockout plasma cells |
IgA nephropathy
IgA nephropathy is characterized by deposition of polymeric IgA1 in the glomerular mesangium. Charge-dependent binding of polymeric IgA1 to human mesangial cells is a key pathogenic mechanism. Abnormal glycosylation of IgA1, often involving C1GALT1 and its chaperone C1GALT1C1, promotes the formation of immune complexes that deposit in the kidney. This highlights how dysregulated polymeric immunoglobulin binding can drive renal injury.
Mucosal infections and immune deficiency
Defects in polymeric immunoglobulin binding and transcytosis compromise mucosal immunity, leading to increased susceptibility to infections. The pIgR-mediated transport of dimeric IgA and pentameric IgM is essential for immune exclusion at mucosal surfaces. Conditions that reduce pIgR expression or function can impair secretory IgA and IgM production, weakening the first line of defense.
Inflammatory and autoimmune conditions
Altered polymeric immunoglobulin binding may contribute to chronic inflammation when immune complexes are not efficiently cleared. In IgA nephropathy, mesangial binding of polymeric IgA triggers inflammatory signaling and matrix expansion. Understanding these interactions may inform therapies targeting polymeric immunoglobulin clearance.
From polymeric immunoglobulin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PIGR abolish polymeric IgA transcytosis? | PIGR knockout epithelial cell line (e.g., MDCK or Caco-2) |
| Does a point mutation in PIGR affect IgA binding affinity? | Point-mutation knock-in of PIGR in epithelial cells |
| Can tagged pIgR track transcytosis in live cells? | Knock-in of fluorescent tag at the PIGR locus |
| Does overexpression of JCHAIN enhance polymeric IgA formation? | Overexpression of JCHAIN in IgA-producing cells |
| Does altered IgA1 glycosylation increase mesangial binding? | Knockout of C1GALT1 in IgA1-expressing cells |
| Can engineered nanobodies block polymeric IgA binding? | Nanobody-displaying flagellar nanotubes in binding assays |
How to Study the polymeric immunoglobulin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Binding of polymeric IgA/IgM to immobilized receptor | Screening for binding specificity |
| Surface plasmon resonance | Real-time binding kinetics and affinity | Characterizing pIgR-IgA interactions |
| Transcytosis assay | Transport of immunoglobulins across epithelial monolayers | Functional validation of pIgR-mediated transport |
| Mass spectrometry | Glycosylation profile of IgA1 | IgA nephropathy research |
| Fluorescence microscopy | Cellular localization and trafficking of pIgR and ligands | Live-cell imaging of transcytosis |
| Nanobody binding assay | Binding of engineered nanobodies to polymeric immunoglobulins | Development of targeted tools |
| CRISPR knockout screening | Identification of genes required for polymeric immunoglobulin binding | Functional genomics of mucosal immunity |
| Bioinformatics analysis | Prediction of binding interfaces and glycosylation sites | Structural modeling of pIgR-IgA complexes |
Binding assays
Enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR) can measure the affinity and specificity of polymeric immunoglobulin binding to pIgR or other receptors. These methods use purified dimeric IgA or pentameric IgM as ligands.
Transcytosis assays
Polarized epithelial cell monolayers grown on transwell filters are used to measure transcytosis of polymeric immunoglobulins from the basolateral to the apical side. This assay quantifies the functional consequence of binding.
Glycosylation analysis
Mass spectrometry and lectin-based assays can characterize O-glycosylation of IgA1, which affects polymeric immunoglobulin binding and clearance. These methods are relevant to IgA nephropathy research.
Imaging and tracking
Fluorescence microscopy and live-cell imaging of tagged pIgR or labeled immunoglobulins allow visualization of binding, internalization, and transcytosis in real time. Nanobody-displaying platforms can also be imaged to study binding interactions.
How CRISPR Can Be Used to Study GO:0001790 polymeric immunoglobulin binding
Knockout
CRISPR knockout of PIGR in epithelial cell lines abolishes polymeric immunoglobulin binding and transcytosis, providing a clean loss-of-function model to study GO:0001790. Knockout of JCHAIN prevents formation of J-chain-containing polymeric IgA and IgM, indirectly eliminating the ligand for this function.
Point Mutation
Point mutations in PIGR can be introduced to dissect the binding interface with dimeric IgA or pentameric IgM. Such models help identify residues critical for specificity and affinity, and can mimic patient variants.
Knock-in
Knock-in of fluorescent or epitope tags at the endogenous PIGR locus enables tracking of the receptor during transcytosis without overexpression artifacts. Knock-in of disease-associated variants in C1GALT1 or C1GALT1C1 can model abnormal IgA1 glycosylation and its impact on polymeric immunoglobulin binding.
Overexpression
Overexpression of PIGR or JCHAIN in cell lines can enhance polymeric immunoglobulin binding and secretion, facilitating biochemical studies and production of secretory IgA/IgM. Overexpression of IgA1 in mesangial co-culture models can mimic IgA nephropathy-associated binding.
How EDITGENE Supports polymeric immunoglobulin binding Research
Researchers studying polymeric immunoglobulin binding-related genes often need to determine whether a candidate gene is causally involved in the binding, transport, or downstream signaling of polymeric IgA and IgM. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for polymeric immunoglobulin binding research.
Frequently Asked Questions About polymeric immunoglobulin binding
What is polymeric immunoglobulin binding?
Polymeric immunoglobulin binding (GO:0001790) is the molecular function of binding to a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes.
What genes are involved in polymeric immunoglobulin binding?
Key genes include PIGR, which encodes the polymeric immunoglobulin receptor, and JCHAIN, which is required for forming polymeric IgA and IgM.
What is the role of pIgR in polymeric immunoglobulin binding?
pIgR binds dimeric IgA and pentameric IgM and mediates their transcytosis across epithelial cells, forming secretory IgA and IgM.
How is polymeric immunoglobulin binding related to IgA nephropathy?
Charge-dependent binding of polymeric IgA1 to mesangial cells contributes to glomerular injury in IgA nephropathy.
What diseases are associated with defective polymeric immunoglobulin binding?
Defects can lead to mucosal immune deficiency and are implicated in IgA nephropathy and inflammatory conditions.
What research methods are used to study polymeric immunoglobulin binding?
Common methods include ELISA, surface plasmon resonance, transcytosis assays, and glycosylation analysis.
Can CRISPR be used to study polymeric immunoglobulin binding?
Yes, CRISPR knockout, knock-in, and point mutation models of PIGR and related genes are powerful tools for dissecting this function.
What is the J chain and why is it important?
The J chain links immunoglobulin monomers into polymeric forms, creating the J-chain-containing IgA and IgM that are recognized by pIgR.
How does glycosylation affect polymeric immunoglobulin binding?
Altered O-glycosylation of IgA1 can change its charge and binding properties, influencing clearance and mesangial deposition.
What cell models are available for polymeric immunoglobulin binding research?
Polarized epithelial cell lines, B-cell lines, and mesangial co-culture models are commonly used, and can be engineered with CRISPR.
Conclusion
Polymeric immunoglobulin binding (GO:0001790) is a specialized molecular function that governs the recognition and transport of J-chain-containing IgA and IgM. Its central mediator, pIgR, is essential for mucosal immunity and secretory immunoglobulin formation. Dysregulation of this function is linked to IgA nephropathy and other inflammatory conditions. Advances in CRISPR-based models and engineered binding proteins continue to illuminate the mechanisms and therapeutic potential of polymeric immunoglobulin binding.
References
- 2. Wei H et al.. 2021. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.. Int J Mol Sci 22(5) PMID: 33668983
- 4. Klein Á et al.. 2018. Nanobody-Displaying Flagellar Nanotubes.. Sci Rep 8(1):3584 PMID: 29483707
- 6. Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy.. Nat Rev Cancer 2(10):750-63 PMID: 12360278
- 8. Leung JC et al.. 2001. Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy.. Kidney Int 59(1):277-85 PMID: 11135081
